Login to Your Account

PDAC gives qualified support to Lucemyra to help with opioid withdrawal

By Mari Serebrov
Regulatory Editor

Wednesday, March 28, 2018

U.S. Worldmeds LLC's Lucemyra (lofexidine) moved another step closer to the U.S. market Tuesday with an 11-1 advisory committee vote recommending FDA approval of the drug to mitigate symptoms of opioid withdrawal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription